ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in Q2 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100730PR_NEWS_USPR_____NY05567) on March 10, 2026, and is solely responsible for the information contained therein.